Navigation Links
Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
Date:10/29/2010

FRANKLIN, Mass., Oct. 29 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the LifeTech Capital 1st Annual Miami Medical Investors Conference being held November 12, 2010 at the JW Marriott Marquis in Miami, Fl. The Company's presentation is scheduled for 11 a.m. ET. Management will be available during the day on November 12 for one-on-one meetings.

In addition, Dr. Mooney has been selected to appear on the "Innovations in Science & Industry" panel with the leading medical researchers from the University of Miami Miller School of Medicine. The panel discussion will take place at 8:30 a.m. on November 12.  

The LifeTech Capital Miami Medical Investors Conference brings together promising biotechnology companies, medical and scientific key opinion leaders with institutional and accredited investors from across the country. More information can be found at http://www.LifeTechCapital.com/conference

About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

Jeffrey Stanlis

Media: Richard SternChairman and Chief Executive Officer

Partner, Hayden IR

Stern & Co.(508) 530-0329

(602) 476-1821

(212) 888-0044
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
2. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
3. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
4. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
5. Cell Therapeutics Third Quarter Net Loss Decreases by 68% in 2010 Compared to 2009
6. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
7. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
8. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
9. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
10. Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
11. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  The Global Health Innovative Technology Fund ... to battle infectious diseases around the globe, today ... could help deliver a range of new innovative ... This latest round of targeted support ... testing a pediatric formulation of a drug considered ...
(Date:3/29/2017)... March 29, 2017 Optometrists have staunchly ... the highest standard in quality and care for ... its objective Wavefront-driven refraction technologies and process to ... enables an unprecedented level of refraction and correction ... relegated to Topgun Navy fighter pilots, but now ...
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global lifestyle drugs market to grow at a CAGR of ... Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... 30, 2017 , ... This morning, more than 275 medical ... support for an independent Vaccine Safety Commission. Five of the signers of the ... hold a press conference at 9:00 AM Friday, March 31 at the ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has ... of more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers ... and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box ...
(Date:3/29/2017)... New York City, NY (PRWEB) , ... March ... ... governing body for men’s and women’s professional squash, announced it has enlisted New ... marketing partner. The agency will develop and procure sponsorship opportunities for the ...
(Date:3/29/2017)... ... ... main cause of hay fever in the United States, with an estimated 95 percent of ... July each year; with the worst time for sufferers being June and July. , ... provide an effective defense against grass pollen; they are proven in independent studies to trap ...
(Date:3/29/2017)... Amherst, Massachusetts (PRWEB) , ... March 30, 2017 , ... ... has had great success and feedback from high school and college students who have ... is being held July 7-23 and YFI is now accepting applications for enrollment. ...
Breaking Medicine News(10 mins):